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Abstract. Lead is one of the most studied clinically important metals due its high 
toxicity and a high number of workers exposed to it. The interest toward Pb is elevated by 
the fact that children are especially susceptible to lead poisoning. Research regarding 
lead poisoning requires a complex, multi-disciplinary (clinical medical and clinical 
chemical) approach. Monitoring human exposure to lead (intake, i.e. poisoning) may be 
achieved by quantification of Pb in tissues and body fluids. For that reason, a number of 
accurate and reliable analytical methods for the determination of Pb (analytical/preanalytical 
variable) were developed. An objective of this review paper is to provide key information 
necessary for proper interpretation of results of lead related clinical/laboratory tests. 
Key words: lead, toxicity, maximum allowed concentration, clinical chemistry, work 
ability estimation 
1. INTRODUCTION 
Lead (Lat. Plumbum, Pb) or Saturn (as referred to by alchemists) is a soft gray-blue 
metal. Lead has had widespread use in trade and industry since the ancient times due to its 
stainless properties and pliability. Ancient Greeks and Romans used lead alloys for the 
production of plumbing systems, household dishes, in shipbuilding, in making wine grails, 
etc; some lead compounds were used in pharmacy, while others, due to their vivid 
coloring, were used as pigments. Lead application was a demonstration of economical 
power in old times, and lead poisoning was one of the oldest professional hazards. 
According to some historians, one of the reasons for the downfall of Roman Empire could 
be sought in high mortality rate and psychological illness and sterility of its citizens; these 
were, apparently, caused by consumption of lead-containing food, wine, and water. One 
of the outcomes of industrial revolution (18
th
 century) was automerization of production 
process; thanks to this, exposure of workers to Pb (and consequentially Pb induced 
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poisonings) was significantly reduced. Sterility, abortion, premature delivery and high 
number of stillborns were some of the consequences of exposure of female workers to 
lead and its compounds. Mentioned problems were observed even in the case of women 
whose husbands were involved in lead production. For these reasons, at the end of the 19
th
 
century, total female workforce was withdrawn from Pb-based industries. 
Despite its well documented and scientifically proven toxicity, lead (40%), its alloys 
(25%) and compounds (35%) are still widely used in industry. For example, lead oxides 
are constituents of electric battery plates, some types of rubber, protective coatings, 
enamels, pigments and glass; some Pb-containing salts are used in agriculture (arsenate is 
an insecticide), rubber and chemical industries; some organolead compounds (tetraethyl 
and tetramethyl lead) are anti-knock additives in gasoline; lead alloys are used for the 
production of letters, pipes, can sheets, cable covers, ammunition etc. 
Lead evaporation or formation of contaminated dust, which may occur during lead 
processing and application, might be regarded as sources of professional lead exposure 
and intoxication. Non-professional risk source is contaminated food, water and air, lead 
item usage or usage of items coated with paint that contains lead. Larger lead content in 
agricultural land can be found near industries that process lead, and near traffic roads due 
to the consumption of gasoline with lead that contains tetraethyl and tetramethyllead. An 
increased lead content has been observed in plants (vital in the food chain) grown on 
contaminated soil [1-5]. 
Nowadays, the cases of acute lead intoxication are relatively rare. However, the 
amount of atmospheric lead is constantly increasing, mainly due to the exhaust gases from 
vehicles. It has been shown that the level of Pb in Greenland ice was 0.0005 mg kg
-1
 in 
800 AD and has progressed to 0.21 mg kg
-1
 till 1965. Lead is still believed to be a main 
cause of various medical disorders. For example, it had been shown (in the study of 
synthesis of hepatic proteins) that laboratory animals with elevated lead load have 
developed fatty liver condition; some renal diseases and hypertension have been related to 
mild lead exposure; intake of even relatively small amounts of lead (lead level in whole 
blood, PbB, 0.5-1.0 μmol L
-1
) seems to be capable to seriously affect mental development 
and decrease intelligence of pre-school children. Thus, no wonder lead is still one of the 
most commonly studied toxic metals (chemical features, biochemical effects, and human 
and environment health issues) [6-9]. 
Diagnosis of lead poisoning is highly complex. Most frequently, its relays on both 
clinical symptoms and the results of laboratory test (here, lead is analytical/preanalytical 
variable). Lead absorption induces changes in endogenous factors. Some factors are 
rapidly modified, while others are modified gradually, depending on the intoxication 
intensity and general health status. Needless to say, the latter precede clinical symptoms 
and offer quantitative information about the level of exposure/absorption and harmful 
lead effects; therefore, they are relevant for diagnosis, both toxicological-clinical and 
analytical-toxicological one and should always be considered in conjunction with the 
patient's history and physical findings, not in isolation. An objective of this review paper 
is to provide key information necessary for proper interpretation of the results of lead 
related clinical/laboratory tests.  
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2. BASIC CONCEPTS OF CLINICAL CHEMISTRY 
Generally speaking, clinical chemistry is nothing else but qualitative and/or quantitative 
chemical analysis of highly complex samples (body fluids, cells, tissues etc.), which 
should enable/facilitate medical diagnosis, treatment control and prevention of health 
disorders. As such, it requires highly multidisciplinary approach and includes the following:  
 Comprehensive analytical methodology (separation methods, optical, immuno-
chemical, hematological, endocrine, special toxicology methods, instrumental 
analysis methods, error theory, information systems etc.) 
 Clinical-chemical identification in clinical medicine (diagnosis, prognosis, prevention, 
therapy control etc.), and 
 Evaluation of the results of clinical-chemical analysis (identification), with the aim 
of identifying interference and other types of impact. 
Proper clinical and chemical identification is provided by: 
 Preanalytical phase, based on the choice of parameters that are to be determined, 
patient preparation for testing and biological material sampling, 
 Analytical phase, which includes the choice of method and analysis process, 
 Postanalytical phase, which includes analytical and medical evaluation of the 
results, and 
 Assessment and consulting with a physician [10, 11]. 
Parameter type that is determined quantitatively is referred to as variable, and each 
separate result is value or data. Parameter that is directly determined is always called 
analytical variable. When analytical variable affects other parameters, it is named 
preanalytical variable. These effects may be uncovered by monitoring differences in the 
results of an appropriate analysis, regarding appropriate endogenous factor. Experimental 
results remain unchanged if preanalytical variable has no significant impact on analytical 
variable [12]. Thus, the results of appropriate chemical tests should be compared to 
reference values, and not only to those for healthy individuals, but also for individuals 
with disorders. Reference values in clinical chemistry are the results of quantitative analysis 
of a substance taken from an individual or a selected group of people chosen on clearly 
defined criteria with risk factors, certain physiological conditions, disorders, pharmacologically 
active agents, and so on. Group reference values are frequently required  age, gender, 
race/nationality etc. Certain variables have reference intervals. The concept of reference values 
has been developed by a specific committee: IFCC (International Federation of Clinical 
Chemistry). Biological monitoring results are especially estimated (continuous or periodical 
measurements and study of potentially hazardous substances or their metabolites, or biological 
effects on tissues, secretions, excretions, exhaled air or other, in order to estimate professional 
or ecological exposure and health risk), and they are compared to adequate reference values. 
Reference values are those in use for professionally unexposed population and biologically 
tolerant values for professionally exposed population [13, 14]. 
3. LEAD: EXPOSURE, INTAKE AND TOXICITY 
Maximum allowed concentration (MAC) of lead in living and working environment 
has been established in accordance with standards; their values are as follows: 
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 working environment air < 0.1 mg m-3;  
 flowing water < 0.2 mg m-3; 
 groundwater < 0.06 mg m-3;  
 residential area atmosphere (mean value) < 0.0007 mg m-3; 
 soil 5-25 mg kg-1; 
 human diet 0.1-0.3 mg per day. 
Inorganic lead compounds are absorbed by human organism primarily by inhaling air 
and ingesting food, and penetration through intact skin is negligible. Skin absorption is 
possible only in case of organic compound mediation, i.e. tetraethyl and tetramethyllead 
that are easily dissolved in fat. Ingested lead absorption varies from 10-40% and depends 
on other food ingredients. The intestinal absorption of lead may be modified by certain 
dietary constituents. Tyrosine, arginine and amino acids with sulfhydryl groups (cystine, 
cysteine and methionine), together with certain reducing substances (e.g. ascorbic acid, 
citric acid), increase intestinal lead absorption. Milk, on the contrary, failed to influence 
intestinal lead absorption to any significant degree. But it is also reported that diet with 
low vitamin D, iron, zinc and phosphorus along with milk intake increases lead absorption. 






 is to decrease intestinal Pb
2+
 
absorption. The reasons for this interference are not yet fully explained. Some substances are 




) may well 
compete with lead for absorptive sites in the intestinal mucosa. Lead compounds convert 
into soluble lead chlorides under influence of hydrochloride acid of gastric juice, and by 
bile they are transformed into lead chelates, that are absorbed in intestines. Main 
elemental lead, lead alloy, and lead compound hazard occurs due to its cumulative toxicity in 
which Haber's law (K = CT) is not applicable, where the product of toxic matter 
concentration (C) and exposure time (T) is constant. In accordance with the toxicity scale 
(from 0 to 4), lead and its derivatives are highly toxic (level 3), and the effects can be acute 
and chronic. Lead has hemotoxic, nephrotoxic and neurotoxic impact. 
Lead absorption by inhalation and ingestion is the cause of metal deposition in soft 
tissues (kidney, liver and nervous system), and bones (about 95% of total lead). This leads 
to hematopoiesis disorder and causes biochemical lesions in many stages of the heme 
synthesis pathway. Lead toxicity is proportional to its great capacity to make chemical 
bonds with sulfhydryl protein groups. Enzymes that are involved in heme biosynthesis of 
are lead-sensitive. Heme biosynthesis is performed in every human tissue cell, with the 
highest intensity in erythrocyte cell line in bone marrow (85% of the total heme) where 
hemoglobin is formed. Disorder heme synthesis leads to the accumulation of delta-
aminolevulinic acid (δ-ALA) which creates free radicals by autoxidation.  
Nephrotoxic lead effects, lead nephropathy, occur in professional exposure. Chronic 
irreversible nephropathy may be induced by repeated acute poisoning with high lead 
concentration or long-term exposure (lead concentration in blood 3.38 μmol L-1 over a 
period of 10 years). These effects are characterized by progressive loss of renal function, 
often followed by hypertension. The impairment mechanism is not completely understood, 
but the presence of hypertension may be explained with renal disorder and spasmogenic 
lead effect on the smooth muscles of blood vessels. 
Changes in the nervous system (central, peripheral and autonomous) arise in the 
presence of PbB concentration of 0.8-1.2 mg L
-1
. 
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Chronic lead poisoning (saturnism) is important from the toxicological point of view. 
Lead poisoning occurs due to the inability of an organism to compensate for the increased 
absorption. Many pathological conditions influence the biological capacity and absorption, thus 
increasing the risk of poisoning. These include: infectious diseases, acute and chronic 
bronchitis, anemia, nervous system anomalies, gastrointestinal system effects, personal hygiene 
level, etc. 
Firstly, lead poisoning safety aim is to prevent lead vapor inhalation by applying 
technical prevention measures in industries, and secondly, to prevent lead intake via 
contaminated food and water. The role of health protection is to prevent diseases, which 
is conducted by occupational medicine via the following: 
 medical examination prior to employing workers (screening for alcohol addicts or 
individuals who suffer from mental illnesses or hypotension, in order to prevent 
their professional engagement on locations with possible Pb contact),  
 periodical medical examination for each employee (in order to evaluate physical 
and emotional reactions in general, reactions to the environment), and in particular 
 targeted medical examination of employees under special surveillance, such as workers 
recuperated from lead poisoning or patients recovering from certain diseases. 
In case of identifying a disease, clinical testing and monitoring is required. The role of 
clinical laboratory is to assess each requirement (hematological, toxicological, biochemical) 
in accordance with analytical parameters determined in human samples (blood, serum, 
plasma, urine, etc.), chosen by a clinical toxicologist [15-18]. 
4. LEAD IN HUMAN MATERIAL: REFERENCE VALUES 
Reference values for Pb in various biological (human) samples are as follows: 
 hair and nails < 29 μg g-1;  
 skin (tetraethyl- and tetramethyllead) < 0.005 mg m-3; 
 bones < 70 μg g-1 wet mass; 
 urine < 50 μg g-1 creatinine; 
 urine (biological value) < 150 μg g-1 creatinine; 
 urine (Pb-elemental and inorganic compounds) < 0.39 µmol L-1; 
 urine (tetraethyl-lead exposure) < 0.53 µmol L-1;  
 urine (biological value, Pb-inorganic) < 0.63 μmol L-1; 
 whole blood in children < 1.21 μmol L-1; 
 whole blood in adults < 1.93 μmol L-1; 
 whole blood (Pb-elemental, and inorganic compounds) < 2.88 µmol L-1; 
 whole blood (biological value, Pb-inorganic at the end of shift) < 3.38 μmol L-1; 
 whole blood (toxic effects) ≥ 4.83 μmol L-1; 
 stable lead isotope distribution in whole blood: 204 (1.4%), 206 (24.1%), 207 
(22.1%) and 208 (52.3%), and 
 mobilized by chelates: 600 μg per 48 h. 
The amount of lead higher than appropriate reference value in certain biological sample 
(most commonly in whole blood (PbB) and urine (PbU)) is biological marker for lead exposure. 
As already mentioned, the main entry point of lead is the respiratory system. Certain 
amount of lead can be absorbed at this level, but greater amount is absorbed by the 
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pulmonary blood circulation and transported to organs and tissues. Lead distribution to 
tissue is the result of concentration gradient and specific tissue affinity for lead. About 
95% of the total lead load in a human organism is accumulated in bone tissue where it 
partially replaces calcium, out of which the greater part (3/4 of the total lead amount in 
the bones) is unchangeable, irreversible fraction, and the remaining part of 1/4 is 
changeable, reversible fraction that can be redistributed by modifying pH, chelates, 
alcohol, trauma and so on. Lead concentration in bones increases due to aging, especially 
in male individuals. Significantly lower amount of lead is accumulated in soft tissue: liver 
(1.4%), kidney (0.9%), lungs, aorta, grey matter of the cortex and basal ganglia. About 
95% of the total amount of lead in blood is attached to erythrocytes out of which 90% 
attaches to hemoglobin, especially to its γ–chain. Lead bound in erythrocytes does not 
diffuse easily. Lead in ionized state (about 0.3 to 0.4% of lead in blood) is responsible for 
toxic effects. Total lead amount in whole blood is 2% of the total lead amount in the 
body. Biological half life of lead in blood is about 20 days, in soft tissues and irreversible 
fraction about 30-40 days, and in irreversible fraction in bones about 20-30 years. Lead 
passes through the placental membrane and can be found in the fetus (12 to 14 weeks 
after gestation with similar distribution as in adults). 
Lead is excreted via kidneys, primarily glomerular filtration (75-80%), and by the 
gastrointestinal system (about 16%). In a balanced state, the amount of lead excreted by 
urine reflects the amount of lead in blood, and can be used as a biomarker in assessing 
exposure. Lead elimination by the gastrointestinal system is performed either by active 
secretion or passive loss through the appropriate glands (salivary glands, pancreas, 
intestinal glands), by exfoliation and by bile. One portion of lead is reabsorbed and 
submitted to the enterohepatic circulation. The total remaining amount of secreted, 
unabsorbed and reabsorbed lead is discharged through feces. Lead content in feces of 4 
mg per 100 g after a four-week lead exposure proves continuous lead intake by food. 
Other elimination pathways (hair, nails, sweat, milk, teeth, sperm and menstrual bleeding) 
constitute less percentage (about 8%) and less significance, except for the secretion by 
breast milk which poses a risk for the newborn [15, 19, 20]. 
PbB concentration in a balanced state is best shown in soft tissue Pb content (in case of 
recent exposure), and it is not correlated with total lead load in the organism. PbU 
concentration test is a very good indicator of the level of organic lead exposure and 
increased lead absorption. The results of this test are important for monitoring of 
Na2CaEDTA therapy that is used in case of chronic intoxication in order to accelerate lead 
elimination. Na2CaEDTA is distributed mostly in extracellular medium, where ionic exchange 
of Pb with Ca occurs. Newly formed complex Pb-EDTA is soluble, weakly dissociated and is 
excreted by glomerular filtration. Formation of complex with lead bonded to cells is 
considerably slower. Application of chelates in prevention of lead intoxication is not indicated, 
while in lead alkyls poisoning some insignificant improvements are achieved. Calcium 
gluconate, barbiturates, mannitol and BAL (dimercaptol) can also be used in lead 
elimination therapy. PbU concentration is not significant as an early test for inorganic lead 
exposure. It is important to note that a 24-hour aliquot urine sample should be used when 
determining PbU content, without insisting on the numerical value of the volume. Correlation 
can be established between lead and endogenous factors excreted in a 24-hour urine, on 
the one hand, and clinical symptoms related to diuresis, on the other. 
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Determination of microconcentration of PbB, PbU and Pb in hair or nails requires the following 
methods: spectrophotometry of colored complexes with dithizone (diphenylthiocarbazone) with 
previous sample mineralization (the method is adequate in terms of sensitivity and 
precision; the disadvantage is time-consuming analysis, chemical and solution purification, 
and easily contaminable samples), polarographic analysis (–0.25 to –0.60 V) of previously 
mineralized sample and lead sedimentation (higher operating speed compared to dithizone, 
but requires complete mineralization of sample). Electrothermal-atomic absorption 
spectrophotometry (ET-AAS) and flame-atomic absorption spectrophotometry (AAS) are 
also used. Combined method of inductively coupled plasma/mass spectrophotometry 
(ICP/MS) is used for the determination of stable lead isotope content and distribution in 
blood and urine [18, 19, 21, 22]. 
Level of organism failure cannot be determined based on lead content tests that serve 
as isolated indicators. Parameters listed above provide direct and reliable indication on 
lead exposure and absorption; however, they offer only indirect information about 
possible toxic effects on organism in general [20, 23-25]. 
5. (INDIRECT) MARKERS OF LEAD POISONING 
Changes in the activity of δ-aminolevulinic acid dehydratase (D-δALA) or 
porphobilinogen (PBG) synthase, or in levels of free erythrocyte protoporphyrin (FEP), 
zinc-protoporphyrin (Zn-PP), pyrimidine-5'-nucleotidase, δ-ALA, uroporphyrin (UP) and 
coproporphyrin (CP) may be used as indirect biological markers of lead poisoning/intake. 
Reference levels/intervals for these are as follows: 
 D-δALA in erythrocytes > 200 nmol PBG mg-1 HGB min-1; 
 D-δALA in erythrocytes = 139-211 kU L-1;  
 δ-ALA in serum = 1.14-1.75 µmol L-1; 
 δ-ALA in urine = 9.9-53.4 µmol per day; 
 δ-ALA in urine (biological value, Pb-inorganic) < 76.3 μmol L-1; 
 CP in urine = 51-351 nmol per day;  
 CP in urine (male) < 368 nmol per day; 
 CP in urine (female) < 336 nmol per day; 
 PBG in urine < 8.8 μmol per day; 
 UP in urine < 50 µg per day; 
 FEP < 0.4-1.6 µmol L-1 erythrocytes. 
Various reference intervals for FEP might be expressed in various ways: as porphyrine 
level per dl of whole blood, dl of erythrocytes, g of hemoglobin, or per mol of heme.  
It seems that the relative amount of lead in blood sufficient to inhibit almost every 
enzyme involved in heme biosynthesis (especially D-δALA and ferrochelatase (heme 
synthetase)) is PbB 0.4 mg L
-1
 (1.93 μmol L-1). As the result of the inhibition of mentioned 
enzymes, δ–ALA and PBG amounts in urine are elevated (low renal threshold causing 
their low blood concentration levels), along with CP in urine and feces, and uroporphyrin 
(UP) in urine. 
The most sensitive test for early lead exposure is based on its inhibition of D-δALA 
enzyme in erythrocytes. Negative correlation between D-δALA and PbB was found even in 
city residents exposed to very low lead concentrations; it appears that even the lowest 
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possible concentration of PbB can have an impact on the enzyme. Its activity was reduced by 
50% at PbB 0.77 μmol L
-1
. Spontaneous reactivation of D-δALA inhibited by lead was very 
slow. Results of the analysis can prove increased lead exposure in the past. This enzyme can 
also be inhibited by tetraethyllead. D-δALA activity is measured by determination of the 
amount of generated PBG in a specific period of time. The study of D-δALA enzyme 
activity is performed by a standardized internationally verified and accepted enzyme-
spectrophotometry method applicable in inorganic lead exposure control (biomonitoring). 
Interpretation of the result has to be thorough because both acute and chronic alcoholism and 
smoking have a significant impact on the reduction of activity of D-δALA [26-29]. 
Physiological increases of δALA in serum and urine, and CP (ether-extracted 
coproporphyrin III) in urine are in correlation with the increase of lead content in blood: 
 PbB < 0.678 µmol L
-1
, 
δ-ALAS = 0.328 ± 0.025 µmol L
-1
 and 
δ-ALAU = 0.8 ± 0.2 mg g
-1
 creatinine; 
 PbB = 1.207-1.641 µmol L
-1
, 
δ-ALAS = 0.403 ± 0.090 µmol L
-1
 and 
δ-ALAU = 0.9 ± 0.4 mg g
-1
 creatinine, and 
 PbB > 2.65 µmol L
-1
, 
δ-ALAS = 1.117 ± 0.565 µmol L
-1
and 
δ-ALAU = 4.5 ± 2.9 mg g
-1
 creatinine. 
δALA evaluation in poisoning is a more specific and sensitive test than coproporphyrin 
quantification, because coproporphyrin is the most commonly excreted porphyrin during 
secondary porphyrinopathy. Hexachlorobenzene, alcohol, sedatives, hypnotics and certain 
diseases, such as liver disease, myocardial infarction, tyrosinemia and so on, can also be the 
cause of coproporphyrinuria. Quantitative determination of δ- ALA, PGB, CP and UP in 
urine might be achieved by spectrophotometric analysis of the purified (ion exchange/ 
chromatography/extraction with diethyl ether) sample [21, 24]. 
Metabolism disorders related to erythrocytes include inhibition of glucose-6-phosphat-
dehydrogenase, phosphofructokinase, arginase, nicotinamide-adenine-dinucleotide 
synthetase and Na/K adenosine-triphosphatase. ATPase inhibition impairs the function of 
ionic pump in maintaining ionic gradient and leads to ATP energy accumulation; its 
increase inhibits the activity of PBG-synthase, and the accumulated δ–ALA creates free 
radicals by autoxidation. Stimulation of lipid peroxidation dependent on iron is present. 
Concentration of reduced or oxidized glutathione in erythrocytes is lowered and the 
activity of enzymes glutathione peroxidase, catalase, and superoxide-dismutase decreases. 
Lead inhibits iron (Fe) incorporation into heme and competitively excludes copper (Cu) out 
of ceruloplasmin inhibiting its catalytic role in the process of oxidation Fe(II) into Fe(III). As a 
result, iron concentration in serum and copper in erythrocytes are increased physiologically. 
Low selenium (Se) in serum, decrease of mercury (Hg) concentration in urine, and triple 
cadmium (Cd) increase are also the consequences of lead poisoning. In the concentration of 1 
mg L
-1
, lead does not interfere with the determination of iron in serum [30, 31]. 
Quantity of protoporphyrin in erythrocytes is a very good indicator of professional 
lead exposure. D-δALA and FPP activities can be used to observe the intensity (shown by 
the enzyme) and duration (shown by porphyrin) of lead exposure. Zn-PP is formed during 
erythropoiesis due to iron deficiency induced by various etymologies: malnutrition, blood 
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loss, chronic inflammation or chronic lead exposure. A significant increase in free erythrocyte 
protoporphyrin IX or as zinc-chelate (Zn-PP) is present one to three months after lead 
exposure, which confirms the level of metal effect on bone marrow. An increase in 
protoporphyrin in urine has been observed in exposed workers. Before the Zn-PP and 
hematofluorometry based methods, determination of porphyrin in erythrocytes was done 
via acid extraction and formation of free protoporphyrin (free erythrocyte protoporphyrin 
or FEP method). Elevated Zn-PP levels can nowadays be determined directly by means of 
hematofluorometry. Laboratory results must be interpreted cautiously because other 
preanalytical variables (iron deficiency and erythropoietic protoporphyria) may cause 
increase of erythrocyte protoporphyrin [32-34].  
Besides inhibition of hemoglobin synthesis, lead may cause shortening of the 
erythrocyte life. Erythrocyte number in blood (RBC, red blood cell), hemoglobin content 
(HGB), MCHC (Mean Corpuscular Hemoglobin Concentration), MCV (Mean Corpuscular 
Volume), and HCT (HematoCriT) are reduced due to hemolytic anemia. Because of stimulated 
hemolysis (accelerated erythrocyte degradation), the number of reticulocytes is increased, and 
due to pancytopenia, the number of leucocytes and thrombocytes is decreased. The 
manifestation of degenerative regeneration of erythrocytes causes an increase in the number of 
basophilic stippling of erythrocytes (BSE); they are created by the aggregation of partially 
degraded ribosomes as the consequence of pyrimidine-5'-nucleotidase enzyme inhibition. 
Anemia is present at PbB = 0.8 mg L
-1
 or 3.86 μmol L-1 [15, 35-37]. 
Erythrocyte number in urine is increased due to nephrotoxicity, and hemoglobin 
content is increased in acute hemolytic crisis. Urobilinogen content in urine is also 
increased. Red-brown urine color is due to porphyrin and hemoglobin presence. Lead-
sulfide poisoning may cause occult bleeding with diarrhea. Bilirubin content in serum is 
increased due to hemolytic anemia; glucose, alanine and β-aminoazobenzene acid in 
urine, and urea in serum are increased as well due to nephrotoxicity [37]. In case of lead 
encephalopathy, protein content in cerebrospinal liquid is increased. The number and 
motility of spermatozoids are reduced in men who are exposed to large concentrations of 
lead. Uric acid in serum is increased, but uric acid concentration in urine is reduced due 
to nephropathy and low secretion by nephrons. Lead impact on creatinine concentration 
has shown the following results [30, 38-43]: 
 serum creatinine - no change 
 urine creatinine is increased by 30%, and 
 mean value of creatinine clearance is decreased in men and women. 
Medium lead exposure (mean concentration PbB = 1.9 μmol L
-1
) showed significantly lower 
FSH (follicle stimulating hormone) in plasma compared to the control group who showed mean 
PbB = 0.2 μmol L
-1
. In female workers under 40 who were professionally exposed to lead, low 
LH (luteinizing hormone) concentrations in plasma were within reference values or without 
confirmed physiological effects. Experimental data has shown that there is no significant 
physiological impact of professional exposure on testosterone levels, TSH (thyroid stimulating 
hormone) and T3 (triiodothyronine), but in severe exposure, a negative poisoning impact on T4 
(thyroxine) and fT4 (free, unbound thyroxine) is noted [39, 40, 44]. 
Lead alkyls do not impact heme biosynthesis; therefore, no increase of porphyrin 
concentration or their precursors can be found during poisoning. There is no anemia or 
basophilic stippling. Diagnosis is confirmed by elevated PbU concentrations and no other 
toxic marker findings. 
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6. LEAD POISONING: CONCLUDING REMARKS  
Laboratory tests for lead poisoning status examining, as preanalytic variable can be 
classified into two groups of identifying the analytic variables: first group - metal content 
evaluation, and second group - lead-dependent variable evaluation. Analytical processes for 
limited human sample analysis must be distinctly sensitive, precise and reliable. Procedures 
must be done with great caution in order to make the differences between reference and 
experimental values as unbiased as possible, in order to observe, identify and monitor lead-
detrimental changes during exposure or treatment. These requirements can be fulfilled only by 
laboratories with specialized experience and technological capacity for measuring trace metals. 
Fully skilled personnel and continuous additional training of employees, analytical 
procedure and laboratory equipment selection for multidisciplinary analyses for determining 
lead poisoning status - all depend on education and skill levels for applying wide-range 
analytic variable tests. Attention should be paid to selection and modernization of methods 
which can be applied conveniently and beneficially for clinic practitioners. Depending on the 
number and features of endogenous parameters to be determined, and available laboratory 
conditions, the time consumed for result acquisition may cover a few minutes to several 
hours, up to 24 hours; longer period than this is usually of little use to clinicians. 
Laboratory search results in analysis and biological marker evaluation for lead exposure 
and its effects (PbB, PbU, D-δALA, FEP or Zn-PP, δ-ALA, CP and other), besides patient 
history and clinical manifestation, should help dictate the classification of worker ability that 
can be temporarily or permanently lost because of lead exposure or threat. 
Long-term disorders of markers suffice to affirm professional lead poisoning in legal 
manner in accordance with other criteria stated by law. Since their quantitative changes are 
determined exclusively by applying substantial analytic methodology in laboratories, it is a 
task and obligation for laboratories to provide accurate clinical-chemical testing by means of 
correct application of preanalytic, analytic and postanalytic phases. Laboratories should also 
be responsible for the process of communicating and distributing results [8, 23, 45]. 
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OLOVO - PREANALITIČKA/ANALITIČKA VARIJABLA 
U KLINIČKOJ HEMIJI 
Olovo spada u red najizučavanijih klinički relevantnih metala zbog svoje toksičnosti i broja radnika 
izloženih ovom metalu. Povećano interesovanje prema ovom metalu je posledica i toga što su deca 
naročito podložna trovanju njime. Ispitivanja koja se tiču trovanja olovom zahtevaju kompleksan, 
multidisciplinaran (kliničko-medicinski i kliničko-hemijski) pristup. Monitoring izlaganja olovu (unos, 
odnosno trovanje) se može ostvariti kvantifikacijom Pb u tkivima i telesnim tečnostima. Iz tog razloga je 
razvijen veliki broj preciznih i pouzdanih metoda za njegovo određivanje (analitička/preanalitička 
varijabla). Cilj ovog preglednog članka je da sumira ključne informacije neophodne za valjanu 
interpretaciju rezultata kliničkih/laboratorijskih testova vezanih za olovo. 
Ključne reči: olovo, toksičnost, maksimalna dozvoljena koncentracija, klinička hemija, ocena 
radne spospobnosti 
